CAS: 1334237-71-6; S-(((S)-2-Acetamido-3-(((R)-1-(((R)-1-(((R)-1-(((R)-1-(((R)-1-(((R)-1-Amino-5-Guanidino-1-Oxopentan-2-yl)Amino)-1-Oxopropan-2-yl)Amino)-5-Guanidino-1-Oxopentan-2-yl)Amino)-5-Guanidino-1-Oxopentan-2-yl)Amino)-5-Guanidino-1-Oxopentan-2-yl)Amino)-1-Oxopropan

结构式图片

合成工艺路线路线简述

    维拉卡肽置于盐酸,氯化铵体系中,用 水 用作溶剂,化学反应生成维考西肽盐酸盐
    参考文献: An Improved Process For The Preparation Of Etelcalcetide Hydrochloride[fr] Procédé Amélioré Pour La Préparation De Chlorhydrate D'ételcalcétide
    标题: An Improved Process For The Preparation Of Etelcalcetide Hydrochloride[fr] Procédé Amélioré Pour La Préparation De Chlorhydrate D'ételcalcétide
    摘要:本发明涉及一种改进的制备etelcalcetide盐酸盐的方法,其化学式为(I):本发明还提供了一种制备etelcalcetide乙酸盐的方法,其化学式为(Vi),该方法是etelcalcetide盐酸盐的中间体:化学式(Vi).

    专利信息


    专利号:US-2023331778-A1
    优先权日:2020-08-31
    标 题 :An improved process for fmoc synthesis of etelcalcetide
    发明人:LOBO LESTER JOHN; CHANDRAKESAN MURALIDHARAN; DOSHI CHETAN; CHANADAK SHAILESH LALCHAND; YADAV NANDLAL GOPAL; MOHE NIKHIL UMESH; VISHWANATHAN KODANDARAMAN; CHAVRE PRAFUL SHAMRAO
    权利人:USV PRIVATE LTD
    摘要:The present invention relates to an improved process for the synthesis of Etelcalcetide and its analogs by solid phase synthesis of Fmoc protected amino acids in a sequential manner, followed by acetylation of terminal D-cys and cleavage of peptide from solid support. The crude heptapeptide thus obtained is reduced using Tris(2-carboxyethyl) phosphine hydrochloride, purified and oxidized with L-cysteine. The oxidized Etelcalcetide is purified and salt exchanged using a one-step reverse phase chromatography process. The purified Etelcalcetide hydrochloride is then precipitated using organic solvents, concentrated and lyophilized to purity of greater than 99.0%.

    专利号:US-10899791-B2
    优先权日:2017-10-03
    标题 :Method for synthesizing etelcalcetide or salts thereof
    发明人:LEE KWANG-CHUNG; HSIEH KUANG-CHAN; CHENG HUI-WEN; KAO CHIA-SUI; HUANG YA-LING; WANG WEI-SSU
    权利人:CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO LTD
    摘要:The present invention provides a method for synthesizing etelcalcetide or salts thereof, comprising the steps of: (a) synthesizing the D-amino acids in the formula (I) sequentially by Fmoc solid-phase synthesis, using a solid support as a starting material in solid phase peptide synthesis and sequentially synthesizing a D-form amino acid of formula (I) by Fmoc chemistry; deprotecting Fmoc group and acetylating the amino group to obtain a sequence A comprising protecting groups (PG) in the side chain of D-Cys and D-Arg; (b) removing the protecting group in the side-chain of D-Cys of the sequence A to form a sequence B; (c) disulfide formation at D-Cys of the sequence B by (PG)-L-Cys-OH to obtain a sequence C; (d) using a cleavage solution to remove the protecting groups of the sequence C to give etelcalcetide as formula (I). The present invention can shorten the steps and time for preparing Etelcalcetide.

    专利号:WO-2022044030-A1
    优先权日:2020-08-31
    标 题 :An improved process for fmoc synthesis of etelcalcetide

    专利号:EP-4204434-A1
    优先权日:2020-08-31
    标题 :An improved process for fmoc synthesis of etelcalcetide
    杭州德普精细化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.depewchem.com
    电话: 86-571-87630650👤
    📞杭州德普精细化工有限公司 ⚠️参考联系方式

    销售电话:86-571-87630650
    邮箱:sales@depewchem.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Shigematsu T, Fukagawa M, Yokoyama K, Akiba T, Fujii A, Shinoda A, Akizawa T. The influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism. Nephrology (Carlton). 2019 Nov 25. doi: 10.1111/nep.13682. [Epub ahead of print] doi: 10.1186/s13063-019-3707-7.
    3: Russo D, Tripepi R, Malberti F, Di Iorio B, Scognamiglio B, Di Lullo L, Paduano IG, Tripepi GL, Panuccio VA. Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in "Real Life". J Clin Med. 2019 Jul 20;8(7). pii: E1066. doi: 10.3390/jcm8071066.
    4: Cunningham J, Block GA, Chertow GM, Cooper K, Evenepoel P, Iles J, Sun Y, Ureña-Torres P, Bushinsky DA. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int Rep. 2019 Apr 16;4(7):987-994. doi: 10.1016/j.ekir.2019.04.010. eCollection 2019 Jul.

    合成参考文献


    参考文献:10.1186/1471-2369-15-81
    摘要:Walter S, Baruch A, Alexander ST, Janes J, Sho E, Dong J, Yin Q, Maclean D, Mendel DB, Karim F, Johnson RM. Comparison of AMG 416 and cinacalcet in rodent models of uremia. BMC Nephrol. 2014 May 19;15():81.
    参考文献:10.1177/2168479017720248
    摘要:Kondo H, Saint-Raymond A, Yasuda N. What to Know About Medicines With New Active Ingredients Approved in FY 2016 / 2016 in Japan and EU: A Brief Comparison of New Medicines Approved in Japan and the EU in 2016. Ther Innov Regul Sci. 2018 Mar;52(2):214–9. doi: 10.1177/2168479017720248.
    参考文献:10.2147/dddt.s160223
    摘要:Ye J, Deng G, Gao F. Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis. Drug Des Devel Ther. 2018;12():901–9.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知